#USA #Boston #medical technology #Intrinsic Therapeutics #Barricaid

Intrinsic Therapeutics Strengthens Leadership Team

Intrinsic Therapeutics, Inc., a pioneering medical technology firm, has made a strategic move to enhance its sales leadership by appointing industry veterans Mike Lytle and Dave Decker as Vice President of Sales for the West and East regions, respectively. This change is poised to significantly advance the treatment options available for lumbar discectomy patients.

Having a clear focus on redefining standards of care for patients with large annular defects, the company aims to reduce reoperations due to reherniation by an impressive 81% using their innovative Barricaid Annular Closure Device. This device has already demonstrated its value by offering better outcomes to patients recovering from lumbar discectomy surgery.

Keith Valentine, the President and CEO of Intrinsic, expressed optimism regarding these appointments, citing the combined 60 years of experience that Lytle and Decker bring to the table. He commended their leadership skills and strong relationships within the spine community, underlining that their collaboration will be instrumental in achieving the company’s vision to alleviate unnecessary suffering for high-risk discectomy patients.

Experienced Leadership

Mike Lytle comes with over three decades of experience in the medical device industry, specifically 17 years in spine-related fields. He had a notable tenure at Orthofix/SeaSpine, where he consistently led one of the company’s top regions. His passion for the new role stems from personal experiences, having faced complications from a failed multilevel discectomy himself. He emphasized the urgency of providing access to Barricaid for every eligible patient, hoping to spare them the challenges he encountered during his recovery.

Conversely, Dave Decker has also dedicated more than 30 years to spine and orthopedic sales. His recent tenure as AVP at SeaSpine/Orthofix saw the region prosper under his leadership with key metrics showcasing peak performances for three consecutive years. Decker voiced enthusiastic optimism about Barricaid, noting that the device is a significant progression in addressing disc herniation. With Barricaid in their arsenal, he believes surgery can significantly enhance the lives of many patients grappling with chronic back issues.

The Barricaid Advantage

The Barricaid device is designed to prevent reherniation and eliminate the need for reoperation, making it a critical innovation in the field of spinal treatment. Having been implanting in over 12,000 patients, it’s backed by rigorous clinical studies, including randomized controlled trials that showcase its efficacy compared to traditional discectomy methods.

The importance of such advancements cannot be overstated, especially given reports indicating that up to 30% of patients undergoing traditional discectomy surgery may experience reherniation between 6 months to 2 years post-operation. Intrinsic Therapeutics, through innovative technologies like Barricaid, is setting new benchmarks in patient care and outcomes in spine surgery.

Looking Ahead

With Mike Lytle and Dave Decker at the helm of sales, Intrinsic Therapeutics is not just enhancing its leadership but is also positioning itself to foster a significant impact on the treatment landscape for spinal conditions. Their extensive experience and proven track records in sales growth will be crucial as the company strives to ensure that its cutting-edge solutions reach more patients and empower surgeons in improving health outcomes. As the healthcare landscape evolves, the commitment of Intrinsic Therapeutics to innovate and provide effective solutions for its patients continues to shine brightly. Providing life-changing treatments is not just a goal; it’s their mission.